Effects of active form of EGFR on disease-free survival in ovarian cancer women

Abstract

Background

Standard procedure in cases of ovarian cancer includes surgical treatment and complementary chemotherapy based on taxanes and platinum compounds. The results of such a procedure in advanced forms of cancer are still unsatisfactory. More accurate determination of the duration of remission with cancer patients is possible through the identification of prognostic factors. Currently adopted and extensively used prognostic factors include, among others, the age of the patient at the moment of the disease being diagnosed, the degree of clinical advancement, the size of the tumour remaining after surgery, the histological type of the neoplasm, and the volume of fluid in the peritoneal cavity. Among neoplasm markers the greatest importance is attributed to the CA 125 antigen, but continued efforts are being made in the search for new, more specific and sensitive markers.

Aim

The objective of the study presented herein was estimation of the prognostic significance of the active form of EGFR in the serum of women with ovarian cancer in relation to their disease-free survival time.

Materials/Methods

The study was performed on 100 women treated for ovarian cancer in the course of four years. The concentration of the active form of EGFR was determined in the blood serum, prior to treatment, using commercial immunoenzymatic sets. Disease-free survival was defined as the time elapsed from the completion of complementary first-line chemotherapy till the appearance of clinical and/or biochemical (CA 125>30 U/ml) symptoms of relapse of the neoplastic disease.

Results

The concentration of the active form of EGFR fell within the range of 0.093–0.475 fmol/ml and did not show statistical significance with relation to disease-free time: the duration of the remission period was similar in patients with low as well as with high concentration of the active form of that receptor.

Conclusions

Examination of concentration of the active form of EGFR in blood serum prior to surgery does not display prognostic significance for prediction of the length of the period of remission or of disease-free survival.